ViiV Healthcare

ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline (GSK) and Pfizer, which are global pharmaceutical companies. The company's aim is to take a deeper and broader interest in HIV/AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV.

History

ViiV Healthcare was established in 2009 by GlaxoSmithKline and Pfizer. In 2012, Shionogi, a Japanese pharmaceutical company, joined the company. The company was formed to focus on the progression and innovation of therapies for HIV and AIDS.

Products

ViiV Healthcare's portfolio includes a range of antiretroviral medicines, including integrase inhibitors, nucleoside reverse transcriptase inhibitors (NRTIs), and non-nucleoside reverse transcriptase inhibitors (NNRTIs). Some of their notable products include Dolutegravir, Abacavir, and Lamivudine.

Research and Development

ViiV Healthcare is committed to advancing research and development of new HIV medicines and innovations in patient care. The company is actively involved in numerous research studies and clinical trials, with a focus on treatment-experienced patients and those with resistance to current therapies.

Community Involvement

ViiV Healthcare is deeply committed to community involvement and has established the Positive Action program to support community initiatives that improve the lives of people living with HIV. The program supports projects in over 40 countries.

See Also

• GlaxoSmithKline
• Pfizer
• Shionogi
• HIV/AIDS
• Antiretroviral therapy

This HIV related article is a stub. You can help WikiMD by expanding it.